-
WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing
4.17.2019Biotechnology company Inozyme Pharma, Inc. announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments.
-
Four Things Every Smart Startup Should Do as It Scales
4.10.2019This article discusses key areas that startups need to focus on as they mature in order to sidestep “business-busting” distractions and lay the groundwork for healthy company culture.
-
Recent Venture Financings as Company Counsel: 2019
3.14.2019In 2018, we served as counsel in more than 200 venture financings raising close to $4.5 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Advises Schrödinger in $85 Million Financing Round
1.4.2019Schrödinger, a privately held company revolutionizing drug discovery through advanced molecular simulations, announced on January 4, 2019 the closing of an $85 million financing to support continued growth and innovation of its computational platform and expansion of its drug discovery pipeline.
-
You’ve Closed Your Financing Round. Congratulations. Now What?
10.27.2018In an article published by VentureBeat, Partner Gary Schall lays out the critical post-financing actions that startups should take after closing their financing rounds.
-
2018 Venture Capital Report
6.22.2018The 2018 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as provides a look at key issues to consider.
-
2018 IPO Report
6.22.2018The 2018 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest.
-
2018 M&A Report
6.22.2018The 2018 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2018 IPO, Venture Capital and M&A Reports
6.22.2018WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing
6.20.2018Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, announced on June 19, 2018, the closing of a $55 million Series C financing.
-
WilmerHale Counsels Accent Therapeutics in $40M Series A Financing
5.22.2018On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing.
-
Contemplating an ICO? It’s All Fun and Excitement Until the SEC Comes to Call
5.1.2018In the case of initial coin offerings (ICOs), the law is laid down by the US Securities and Exchange Commission. Over the past few months, this agency has been ramping up its warnings about ICOs that fail to comply with US securities laws. Read this article published by Bloomberg Law's Securities Regulation & Law Report, written by Jennifer Zepralka and Glenn Luinenburg.
-
You’ve Signed a Term Sheet for Your First Equity Financing. Congratulations! … Now What?
4.12.2018Gary Schall, in this article published by The Recorder, shares six critical steps founders can take to forge a strong and open relationship with their new business partners.
-
Standardized Term Sheets May Not Protect Your Interests
4.6.2018An article by Joshua Fox, published by Law360, focusing on standardized term sheets and how they may inadvertently gloss over or neglect issues that can be critical to founders' long-term success.
-
Founders, Pay Attention to This Stuff—Not the Stock Market
3.23.2018An article by Daniel Zimmermann, published by Xconomy. The article discusses information that entrepreneurs should follow and what they can safely dismiss.
